BioAge Labs, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases by targeting the biology of human aging, reported a net loss of $80.6 million for the year ended December 31, 2025, compared to a net loss of $71.1 million for the previous year. The increase in losses was attributed to higher research and development expenses, which rose by 25% to $73.9 million, primarily due to increased costs associated with the development of its lead product candidate, BGE-102, and other programs. The company recognized $9.0 million in collaboration revenue from its agreement with Novartis, marking a significant increase from no collaboration revenue in 2024.
The company’s total operating expenses for 2025 were $101.8 million, a 30% increase from $78.2 million in 2024. General and administrative expenses also saw a notable rise, increasing by 45% to $27.8 million, driven by higher personnel-related costs and legal fees. BioAge Labs has not yet generated any product revenue since its inception in 2015 and continues to rely on external funding to support its operations. As of December 31, 2025, the company had $285.1 million in cash, cash equivalents, and marketable securities, which it estimates will be sufficient to fund operations through 2029.
Strategically, BioAge Labs is advancing BGE-102, a small-molecule NLRP3 inhibitor, in two therapeutic areas: cardiometabolic disease and ophthalmology. The company reported promising interim Phase 1 data, showing an 86% median reduction in high-sensitivity C-reactive protein (hsCRP) levels in obese participants, indicating potential for significant cardiovascular risk reduction. Additionally, the company plans to initiate a Phase 2a proof-of-concept trial for BGE-102 in patients with obesity and elevated hsCRP in the first half of 2026, with results expected by the end of that year.
BioAge Labs is also developing apelin receptor APJ agonists for obesity and has entered into collaborations with Eli Lilly and Novartis to expand its pipeline. The company’s workforce consisted of 62 employees as of December 31, 2025, with a significant portion engaged in research and development activities. The company continues to face challenges typical of clinical-stage biopharmaceutical firms, including the need for substantial capital to fund ongoing research and development, as well as the inherent risks associated with drug development and regulatory approval processes.
Looking ahead, BioAge Labs remains focused on advancing its clinical programs and expanding its product pipeline. However, the company acknowledges the uncertainties and risks associated with drug development, including potential delays in clinical trials and the need for additional funding. The successful commercialization of BGE-102 and any future product candidates will depend on the company’s ability to navigate these challenges and secure necessary regulatory approvals.
About BioAge Labs, Inc.
BioAge Labs, Inc. is a biopharmaceutical company focused on developing therapies for metabolic diseases by targeting the biology of human aging. Its platform leverages longitudinal human datasets and multi-omic profiling to identify novel targets like NLRP3 and apelin. The company develops oral, brain-penetrant small molecules and collaborates with major pharma firms to create innovative treatments for obesity and age-related conditions.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.